Pharmacokinetic evaluation of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in patients by positron emission tomography

Journal of Clinical Oncology

Volumn 19, Issue 5, 2001, Pages 1421-1429

  Saleem, A ^a   Harte, R J ^a   Matthews, J C ^a   Osman, S ^a   Brady, F ^a   Luthra, S K ^a   Brown, G D ^a   Bleehen, N ^a   Connors, T ^a   Jones, T ^a   Price, P M ^a   Aboagye, E O ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 11; DRUG METABOLITE; N (2 DIMETHYLAMINOETHYL) 4 ACRIDINECARBOXAMIDE; TRACER;

ADVANCED CANCER; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG SCREENING; DRUG STRUCTURE; DRUG UPTAKE; FEMALE; HEART MUSCLE; HUMAN; MALE; PHASE 1 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOACTIVITY; TUMOR BLOOD FLOW;

EID: 0035281913     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.5.1421     Document Type: Article

References (19)

1. Potential antitumor agents: 50. In vivo solid-tumor activity of derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide
2. In vitro assessment of N-[2-(dimethylamino)ethyl]acridine-4- carboxamide, a DNA-intercalating antitumour drug with reduced sensitivity to multidrug resistance
3. Design of DNA intercalators to overcome topoisomerase II-mediated multidrug resistance
4. Selectivity of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide towards Lewis lung carcinoma and human tumour cell lines in vitro
5. Experimental solid tumour activity of N-[2-(dimethylamino)ethyl]-acridine-4-carboxamide
6. Comparison of the blood-brain barrier and liver penetration of acridine antitumor drugs
7. Pharmacokinetics and toxicity of the antitumour agent N-[2- (dimethylamino)ethyl]acridine-4-carboxamide after i.v. administration in the mouse
8. Studies on the metabolism of the novel antitumor agent [N-methyl]N- [2-(dimethylamino)ethyl]acridine-4-carboxamide in rats and humans prior to phase I clinical trials
9. Phase I and pharmacokinetic study of DACA (XR5000): A novel inhibitor of topoisomerase I and II - CRC Phase I/II Committee
10. Phase I study of the cytotoxic agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide
11. A phase I study of XR5000(DACA) by 120 hour intravenous infusion
12. Carbon-11 labelling of the antitumour agent N-[2- (dimethylamino)ethyl]acridine-4-carboxamide (DACA) and determination of plasma metabolites in man
13. 11C]buprenorphine from 3-O-trityl protected precursors
14. Theory of image reconstruction in computed tomography
15. A software system for interactive and quantitative visualization of multidimensional biomedical images
16. Measurements of blood flow and exchanging water space in breast tumors using positron emission tomography: A rapid and noninvasive dynamic method
17. Tumor, normal tissue, and plasma pharmacokinetic studies of fluorouracil biomodulation with N-phosphonacetyl-L-aspartate, folinic acid, and interferon alfa
18. Metabolism of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in cancer patients undergoing a phase I clinical trial
19. Intraperitoneal administration of the antitumour agent N-[2- (dimethylamino)ethyl]acridine-4-carboxamide in the mouse: Bioavailability, pharmacokinetics and toxicity after a single dose